ライフサイエンスコーパス: P2Y(12) receptor

1 in was potentiated by ADP acting through the P2Y12 receptor.

2 y active, and its activity is potentiated by P2Y12 receptors.

3 ATP release, and microglial response through P2Y12 receptors.

4 d an autocrine ADP-mediated response through P2Y12 receptors.

5 addition to that derived from antagonism of P2Y12 receptors.

6 CysLT1R and CysLT2R but not in mice lacking P2Y12 receptors.

7 ated by adenosine-5'-diphosphate through the P2Y(12) receptor.

8 receptor present on platelets, that is, the P2Y(12) receptor.

9 ing that they do not directly antagonize the P2Y(12) receptor.

10 of the functional responses of the platelet P2Y(12) receptor.

11 ically among these mutants and the wild-type P2Y(12) receptor.

12 h the extracellular cysteine residues on the P2Y(12) receptor.

13 ) to ADP, the specific agonist of P2Y(1) and P2Y(12) receptors.

14 ressing high levels of recombinant P2Y(2) or P2Y(12) receptors.

15 naling pathways linked to the P2X4, P2X7 and P2Y(12) receptors.

16 The P2Y(12) receptor, activated by ADP, plays a central role

17 ependent in part on G(i) stimulation through P2Y(12) receptor activation by secreted ADP.

18 d in the initiation of platelet aggregation, P2Y12 receptor activation appears to account for the bul

19 process outgrowth to damaged tissue requires P2Y12 receptor activation but is unaffected by blocking

20 Furthermore, we show that P2Y12 receptor activation is not required for protease-a

21 osine 5'-triphosphate), an antagonist of the P2Y(12) receptor, also did not differ dramatically among

22 rugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the

23 The cloning of the P2Y(12) receptor and its subsequent knockout in mice pro

24 nstitutively active mutant of human platelet P2Y(12) receptor and the identification of potent invers

25 of a local thrombus, dual inhibition of the P2Y12 receptor and calcium mobilization result in a comp

26 is dependent on both the G(alpha)(i)-coupled P2Y12 receptor and the G(alpha)(q)-coupled P2Y1 receptor

27 mole inhibit platelet function by inhibiting P2Y12 receptors and platelet phosphodiesterase, respecti

28 de bridges with both Cys17 and Cys270 in the P2Y(12) receptor, and thereby inactivate the receptor.

29 supporting pleiotropic effects coupled with P2Y12 receptor antagonism.

30 A protein kinase C inhibitor GF 109203X or a P2Y(12) receptor antagonist AR-C69931MX partly reduced G

31 AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS

32 Ticagrelor is a P2Y(12) receptor antagonist that showed superior clinica

33 47, LY640315), a novel potent thienopyridine P2Y(12) receptor antagonist, has the potential to achiev

34 agrelor is the first reversibly binding oral P2Y(12) receptor antagonist.

35 s a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inh

36 ubstituents on the ribose and base conferred P2Y12 receptor antagonist properties to these molecules

37 The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the inci

38 The P2Y12 receptor antagonist ticagrelor has been shown to b

39 escribed an additional mode of action of the P2Y12 receptor antagonist ticagrelor.

40 On the other hand, apyrase, the P2Y12 receptor antagonist, AR-C67085, and indomethacin o

41 However, pretreatment of platelets with P2Y12 receptor antagonist, AR-C69331MX did not interfere

42 on of platelets with aspirin, but not with a P2Y12 receptor antagonist, caused a marked reduction in

43 d by either the integrin inhibitor RGDS or a P2Y12 receptor antagonist, indicating a requirement for

44 Physicians considering prescription of P2Y12-receptor antagonist for long-term (>1 year) protec

45 heral arterial disease, or following a brief P2Y12-receptor antagonist interruption, whereas clopidog

46 in platelet activation and is the target of P2Y(12) receptor antagonists that have proven therapeuti

47 Platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with

48 lar patients who smoke benefit from platelet P2Y12 receptor antagonists more than their nonsmoking pe

49 ntagonists), cyclopentyltriazolopyrimidines (P2Y12 receptor antagonists), anti-von Willebrand factor

50 al study, consisting of the thienopyridines (P2Y12 receptor antagonists), cyclopentyltriazolopyrimidi

51 morphine and its potential interactions with P2Y12 receptor antagonists, as well as on the central is

52 P2Y12 receptor antagonists, concurrently administered wi

53 As head-to-head comparative trials between P2Y12-receptor antagonists are lacking, selection of a s

54 r and inside-out signaling from the P2Y1 and P2Y12 receptors are necessary for phospholipase A(2) act

55 Platelet P2Y12 receptors are the targets of very widely used anti

56 namides, which are potent antagonists of the P2Y12 receptor, are presented.

57 Prasugrel P2Y(12) receptor blockade is associated with greater pha

58 The powerful antithrombotic effects of P2Y12 receptor blockers may, in part, be mediated by pro

59 P did not require Gi signaling or functional P2Y12 receptors but was mediated through activation of a

60 the reactive cysteine residues on the human P2Y(12) receptor by site-directed mutagenesis using pCMB

61 Both P2Y1 and P2Y12 receptors can also undergo PMA-stimulated internal

62 In platelets from a P2Y12 receptor-defective patient, alpha-thrombin, SFLLRN

63 rful synergism is explained by blockade of a P2Y12 receptor-dependent, NO/cGMP-insensitive phosphatid

64 Cys97Ser and Cys175Ser mutants of the P2Y(12) receptor did not express when transfected into C

65 epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) f

66 thus reduces surveillance, whereas blocking P2Y12 receptors does not affect membrane potential, rami

67 Here we show that blockade of platelet P2Y12 receptors dramatically enhances the antiplatelet p

68 hat microglia from mice lacking G(i)-coupled P2Y(12) receptors exhibit normal baseline motility but a

69 P2Y12 receptor expression by LAD2 cells is required for

70 P2Y12 receptor expression permits LTE4-induced activatio

71 26 directly and indirectly affects ADAM9 and P2Y12 receptor expression.

72 idges linking its extracellular domains, the P2Y(12) receptor has 2 free cysteines in its extracellul

73 As the P2Y(12) receptor has been shown to activate G protein-ga

74 pCMBS inactivated the wild-type P2Y(12) receptor in a concentration-dependent manner, wh

75 ls are important functional effectors of the P2Y(12) receptor in human platelets.

76 The discovery of the role of P2Y(12) receptor in platelet aggregation leads to a new

77 The role of the G(i)-coupled platelet P2Y(12) receptor in platelet function has been well esta

78 Activation by ADP of both P2Y(1) and P2Y(12) receptors in platelets contributes to platelet a

79 ently identified functional effector for the P2Y12 receptor, in the regulation of ADP-induced TXA2 ge

80 ls of inhibition of platelet aggregation via P2Y(12) receptor inhibition, not only for the prevention

81 treatment platelet reactivity and incomplete P2Y12 receptor inhibition are risk factors for SAT.

82 stenting and treatment strategies to improve P2Y12 receptor inhibition in patients with high post-tre

83 phoprotein phosphorylation levels to measure P2Y12 receptor inhibition were determined (n = 20) and c

84 pidogrel metabolism, potentially attenuating P2Y12 receptor inhibition.

85 with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated.

86 studies, mice were treated with the platelet P2Y12 receptor inhibitor clopidogrel or placebo.

87 sk in major bleeding by combining aspirin, a P2Y12 receptor inhibitor, and an anticoagulant.

88 me (ACS) patients are not pre-treated with a P2Y12 receptor inhibitor, and percutaneous coronary inte

89 d to treat excessive bleeding in patients on P2Y12 receptor inhibitors (RI).

90 P2Y12 receptor inhibitors clinically in use such as clop

91 after discharge for beta-blockers, platelet P2Y12 receptor inhibitors, statins, and angiotensin-conv

92 ess and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.

93 Blocking P2Y12 receptor is a clinically well-validated strategy f

94 Thus, the P2Y12 receptor is required for proinflammatory actions o

95 uated by PKC inhibitors, whereas that of the P2Y12 receptor is unaffected.

96 osine diphosphate (ADP)-reactive purinergic (P2Y12) receptor is required for LTE4-mediated pulmonary

97 Because clopidogrel antagonizes the platelet P2Y12 receptor, it is widely prescribed for patients wit

98 P2X(4), P2X(5), P2X(7), P2Y(2), P2Y(11), and P2Y(12) receptors localized to the cytoplasm.

99 y rapid feedback amplification that involves P2Y(12) receptor-mediated activation of Syk.

100 nts, but had no effect on Cys17Ser/Cys270Ser P2Y(12) receptor-mediated inhibition of adenylyl cyclase

101 Ligand docking on P2Y1 and P2Y12 receptor models was guided by mutagenesis results,

102 In platelets from mice lacking the P2Y12 receptor, neither alpha-thrombin nor AYPGKF caused

103 , and/or ATP; (iii) the activation of P2X(1)/P2Y(12) receptors on adjacent PLTs; and (iv) the recursi

104 signaling, via selective stimulation of the P2Y(12) receptor or alpha(2A)-adrenergic receptor, respe

105 ntial signalling and cell activation through P2Y12 receptor or receptor heterodimers but no specific

106 The P2Y(12) receptor (P2Y(12)) plays a central role in ampli

107 ding motif of the platelet G protein-coupled P2Y(12) receptor (P2Y(12)R) is required for effective re

108 The human P2Y12 receptor (P2Y12-R) is a member of the G protein co

109 P2Y12 receptor (P2Y12-R) signaling is mediated through G

110 Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of

111 ed BSM contraction is blocked by a selective P2Y12 receptor (P2Y12R) antagonist, PSB 0739 (25 muM), b

112 Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP)

113 The P2Y12 receptor (P2Y12R), one of eight members of the P2Y

114 th tests measuring the adenosine diphosphate-P2Y12 receptor pathway, without significant variations i

115 Platelet P2Y12 receptors play a central role in the regulation of

116 elated factors (higher on-treatment platelet P2Y12 receptor reactivity and premature thienopyridine d

117 Selective blockade of the P2Y(12) receptor results in the inhibition of Syk phosph

118 Unlike AR-C 69931MX, a P2Y(12) receptor-selective antagonist, the GIRK channel

119 ene adenosine 5'-triphosphate (AR-C67085), a P2Y12 receptor-selective antagonist, and adenosine-2'-ph

120 inhibited in the presence of AR-C69931MX, a P2Y12 receptor-selective antagonist, or GF 109203X, a pr

121 or that abolishes secretion, or AR-C66096, a P2Y12 receptor-selective antagonist; alpha-thrombin-indu

122 Cloning of the P2Y12 receptor should facilitate the development of bett

123 PMA reduced subsequent ADP-induced P2Y1 and P2Y12 receptor signaling.

124 ators is ADP, which, acting through platelet P2Y12 receptors, strongly amplifies aggregation.

125 Activation of P2Y(1) and P2Y(12) receptors, through secreted ADP that is stimulat

126 in undergoes synergy with ADP acting via the P2Y12 receptor whereas there is no synergy via the P2Y1

127 ructed a chimeric hemagglutinin-tagged human P2Y(12) receptor with its C terminus replaced by the cor